Yeh Fong Chen

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Trial design issues and treatment effect modeling in multi-regional schizophrenia trials
    Yeh Fong Chen
    Division of Biometrics I, HFD 710, Food and Drug Administration, 10903 New HampshireAvenue, Building 21, Room 4610, Silver Spring, MD 20993 0002, USA
    Pharm Stat 9:217-29. 2010
  2. ncbi Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials
    Yeh Fong Chen
    Division of Biometric I, Office of Biostatistics, Office of Translational Sciences, Center of Drug Evaluation and Research CDER, Food and Drug Administration, Silver Spring, MD 20993 0002, USA
    Contemp Clin Trials 32:592-604. 2011
  3. ncbi Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration
    Ni A Khin
    Division of Psychiatry Products, Office of Drug Evaluation I, Office of New Drugs, Food and Drug Administration, Silver Spring, MD, USA
    J Clin Psychiatry 73:856-64. 2012
  4. ncbi Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications
    Ni A Khin
    Division of Psychiatry Products, HFD 130, Food and Drug Administration, 10903 New Hampshire Ave, Bldg 22, Rm 4110, Silver Spring, MD 20993 0002, USA
    J Clin Psychiatry 72:464-72. 2011
  5. ncbi A bias correction in testing treatment efficacy under informative dropout in clinical trials
    Fanhui Kong
    Division of Biometrics I, Food and Drug Administration, Silver Spring, Maryland 20993, USA
    J Biopharm Stat 19:980-1000. 2009

Detail Information

Publications5

  1. ncbi Trial design issues and treatment effect modeling in multi-regional schizophrenia trials
    Yeh Fong Chen
    Division of Biometrics I, HFD 710, Food and Drug Administration, 10903 New HampshireAvenue, Building 21, Room 4610, Silver Spring, MD 20993 0002, USA
    Pharm Stat 9:217-29. 2010
    ..When baseline body weight was considered as a covariate in an empiric model, our results indicated that it alone did not seem to be an important factor in explaining regional difference...
  2. ncbi Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials
    Yeh Fong Chen
    Division of Biometric I, Office of Biostatistics, Office of Translational Sciences, Center of Drug Evaluation and Research CDER, Food and Drug Administration, Silver Spring, MD 20993 0002, USA
    Contemp Clin Trials 32:592-604. 2011
    ....
  3. ncbi Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration
    Ni A Khin
    Division of Psychiatry Products, Office of Drug Evaluation I, Office of New Drugs, Food and Drug Administration, Silver Spring, MD, USA
    J Clin Psychiatry 73:856-64. 2012
    ....
  4. ncbi Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications
    Ni A Khin
    Division of Psychiatry Products, HFD 130, Food and Drug Administration, 10903 New Hampshire Ave, Bldg 22, Rm 4110, Silver Spring, MD 20993 0002, USA
    J Clin Psychiatry 72:464-72. 2011
    ..This report explores differences in efficacy data from placebo-controlled MDD trials submitted in support of new drug applications (NDAs) over a 25-year period...
  5. ncbi A bias correction in testing treatment efficacy under informative dropout in clinical trials
    Fanhui Kong
    Division of Biometrics I, Food and Drug Administration, Silver Spring, Maryland 20993, USA
    J Biopharm Stat 19:980-1000. 2009
    ....